| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Pharmaprint Inc is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Almat Pharmachem Inc. is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ZO® Skin Health provides a comprehensive range of solutions that will restore skin to a healthy state. From correcting sun damage and pigmentation to acne and aging, ZO® offers a simple, systematic approach to creating and maintaining healthy skin.